| Abatacept | Orencia® | Psoriatic arthritis after DMARDs NICE TA568
appraisal terminated.
NOT recommended for prescribing on the NHS in Lancashire
| Formulary BNF 10.1.3 |
| Abiraterone | Zytiga® | Newly diagnosed high-risk hormone-sensitive metastatic prostate cancer - Not recommended for prescribing on the NHS in Lancashire - NICE TA721 | Formulary BNF 8.3.4 |
| ActiPatch® | ActiPatch® | Chronic pain (presence of pain longer than 3 months) associated with knee osteoarthritis and plantar fasciitis | Forumlary BNF 4.7 |
| Actos® | Actos® | Generic prescribing only | Formulary BNF 6.1
|
| ACWY vaccine | | Travel vaccination | See Position Statement |
| Afatininb | | Locally advanced or metastatic squamous non-small-cell lung cancer after platinum-based chemotherapy Appraisal Terminated | Formulary BNF 8.1 |
| Aflibercept | Zaltrap® | Metastatic colorectal cancer
NICE TAG307
| Formulary BNF 8.1
|
| Agomelatine | Valdoxan® | Major depression | Formulary BNF 4.3
|
| Alectinib | Alecensa® | Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal) NICE TA438 | Formulary BNF 8.1 |
| Alendronate and Vitamin D | Fosavance® | Postmenopausal osteoporosis | Formulary BNF 6.6
|
| Alimemazine tablets and liquid | All brands | antihistamine | Formulary BNF 3.4 |
| Aliskiren | | Non-formulary in line with NHSE low priority prescribing commissioning agenda | Formulary BNF 2>5 |
| Alpelisib | Piqray | NICE is unable to make a recommendation alpelisib with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer NICE TA652 updated by TA816 | Formulary BNF 8>1>5 |
| Amantadine | Lysovir® | Influenza treatment & prophylaxis
NICE TA158, TA168 | Formulary BNF 5.3
|
Amifampridine
| Firdapse® | Lambert-Eaton Syndrome
| Formulary BNF 10.2
|
| Amivantamab | Rybrevant | Treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy in adults. Not recommended, within its marketing authorisation. NICE TA850 | Formulary BNF 8.2.3 |
| Amoxycillin (nebulised) | | Not licensed for use via nebulised route for bronchiectasis or any other indication | Formulary BNF 5.1
|
| Anakinra | Kineret® | Rheumatoid arthritis - NICE TA72
| Formulary BNF 10.3
|
| Angiotensin II | | Vasosuppressor-resistant hypotension caused by septic or distributive shock. NICE TA859 - Terminated appraisal | Formulary BNF 2>7 |
| Anifrolumab | Saphnelo® | Active autoantibody-positive systemic lupus erythematosus - NICE TA793 - Appraisal terminated. Not recommended for prescribing on the NHS in Lancashire | Formulary BNF 10.1 |
| Anti-thymocyte globulin (Riabbit) | Thymoblobuline® | Immunosuppressive therapy for kidney transplant in adults NICE TA481 (adults) NICE TA482 (Children and young adults) | Formulary BNF 8.2 |
| Apremilast | Otezla | Moderate to severe plaque psoriasis. NICE TA368
| Formulary BNF 10.1
|
Aprovel®
| Aprovel® | Generic Prescribing Only
| Formulary BNF 2.5
|
| Aricept® | Aricept® | Generic Prescribing Only
| Formulary BNF 4.11
|
| Thyroid extracts {unlicensed liothyronine and thyroid extract products] | e.g. Armour Thyroid | Hypothyroidism. RMOC liothyronine guidance
UKMI Q&A Statement
Statement from British Thyroid Association
| Formulary BNF 6.2
|
| Asenapine | Sycrest® | Schizophrenia/bipolar mania
| Formulary BNF 4.2
|
| Atezolizumab | Tecentriq® | Untreated advanced non-squamous non-small-cell lung cancer - Not recommended as in NICE TA618 | Formulary BNF 8.1 |
| Atorvastatin chewable tablets | Lipitor chewable® | Hypercholesterolaemia
| Formulary BNF 2.12
|
| Avapritinib | Ayvakit | Unresectable or metastatic gastrointestinal stromal tumours in adults. Terminated Appraisal - NICE TA730 Not recommended for prescribing on the NHS in Lancashire | Formulary BNF 8.1.5 |
| Axicabtagene ciloleucel |
Yescarta |
Not recommended, within its marketing authorisation, for treating relapsed or refractory follicular lymphoma in adults as by NICE TA894 |
Formulary 8.2 |
| Azacitidine | Vidaza® | Acute myeloid leukaemia
NICE TAG399
| Formulary BNF 8.1
|
| Azelastine/ Fluticase | Dymista® | Moderate to severe allergic rhinitis
| Formulary BNF 12.2
|
| Azilsartan | Edarbi® | Hypertension
| Formulary BNF 2.5
|
| Baloxavir marboxil | Xofluza | NICE is unable to make a recommendation on baloxavir marboxil (Xofluza) for treating acute uncomplicated influenza in people aged 12 and over. - Terminated appraisal - NICE TA732 | Formulary 5.3.4 |
| Bazedoxefine | Duavive® | Oestrogen deficiency symptoms.
| Formulary BNF 6.4
|
| BCG vaccine | | Travel vaccination | See Position Statement |
| Belatacept | Nulojix® | Immunosuppressive therapy for kidney transplant in adults NICE TA481 (adults) NICE TA482 (Children and young adults) | Formulary BNF 8.2 |
| Belimumab | Benlysta | NICE is unable to make a recommendation on belimumab (Benlysta) for treating lupus nephritis. [NICE TA806]. Appraisal terminated | Formulary BNF 10.1 |
| Bendamustine | Levact® | Non-Hodgkins lymphoma. NICE TA206
Appraisal terminated. | Formulary BNF 8.1
|
| Bevacizumab | Avastin® | NICE is unable to make a recommendation about the use in the NHS of bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer because no evidence submission was received from Roche.
NICE TA560 | Formulary BNF 8.1 |
| Bevacizumab | Avastin® | Relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.
NICE TA353 Appraisal terminated.
| Formulary BNF 8.1
|
| Bevacizumab | Avastin® | Monotherapy or combination chemotherapy of metastatic colorectal cancer, 2nd line NICE TA242 | Formulary BNF 8.1
|
| Bevacizumab | Avastin® | Lung cancer, NSC NICE TA148
| Formulary BNF 8.1
|
| Bevacizumab | Avastin® | Renal cell carcinoma NICE TA178
| Formulary BNF 8.1
|
| Bevacizumab | Avastin® | In combination with a taxane for metastatic breast cancer, 1st line NICE TA214 | Formulary BNF 8.1
|
| Bevacizumab | Avastin® | Diabetic Macular Oedema
| Formulary BNF 8.1
|
| Bevacizumab | Avastin® | In combination with paclitaxel and carboplatin for 1st line treatment of advanced ovarian carcinoma NICE TA284 | Formulary BNF 8.1
|
| Bevacizumab | Avastin® | In combination with gemcitabine and carboplatin for treating 1st recurrence of platinum-sensitive advanced ovarian carcinoma
NICE TA285 | Formulary BNF 8.1
|
| Bevacizumab | Avastin®
| EGFR mutation-positive non-small-cell lung cancer (terminated appraisal) NICE TA436
| Formulary BNF 8.1 |
| Bezlotuxumab | Zinplava® | Preventing current clostridium difficile infection -appraisal terminated -NICE TA601 | Formulary BNF |
| Biatain-IBU® | Biatain-IBU® | Polyurethane foam film dressing | Wound Care Formulary
|
| Blinatumomab | Blincyto | Previously treated Pghiladelphia-chromosome- positive acute lymphoblastic leukaemia - NICE TA686 [Appraisal terminated] | Formulary 8.2.3 |
| Bortezomib | Velcade® | Multiple myeloma after second or subsequent relapse. terminate appraisal | Formulary 8.1.5 |
| Bosutinib | Bosulif | Untreated chronic myeloid leukamia in adults _ NICE TA576 - appraisal terminated
NOT recommended for prescribing on the NHS in Lancashire
| Formulary 8.1.5 |
| Botulinum Type A | Botulinum Type A | Uncomplicated chronic anal fissure
| Formulary BNF 1.7
|
| Botulinum Toxin Type A | Botulinum Type A | Hyperhidrosis (excessive sweating) in people with social anxiety disorder. | Formulary BNF
NICE CG159 |
| Botulinum Toxin Type A | Botulinum Toxin Type A | Cosmetic purposes. Not available available for cosmetic purposes, including the treatment of facial ageing or excessive wrinkles.
| See resources: |
| Brentuximab vedotin | Adcetris® | Untreated advanced Hodgkin lymphoma NICE TA594 - appraisal terminated. | Formulary BNF 8.1 |
| Brimonidine 3mg/g gel | Mirvaso® | Facial erythema in rosacea | Formulary BNF 13.6
|
| Bromfenac | Yellox® | Postoperative inflammation following cataract surgery | Formulary BNF 11.8
|
| Budesonide oral capsules | Entocort® | 2nd line corticosteroid option in crohn's disease when conventional corticosteroid not tolerated | Formulary BNF 1.5
|
| Buspirone | Buspar® | Anxiety (short term use)
| Formulary BNF 4.3
|
| Cabazitaxel | Jevtana® | Prostate Cancer
| Formulary BNF 8.1
|
| Cannabis based Medicinal products | | Intractable nausea and vomiting, chronic pain and severe treatment-resistant epilepsy. NICE Cannabis-based medicinal products [updated March 2021]
ForManagement of Chronic Pain - See Position Statement | Formulary BNF 4.7 |
| Canakinumab | Ilaris® | Gout NICE TAG281
| Formulary BNF 8.2.4
|
| Cangrelor | Kangrexal® | Reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti-platelet therapy. Appraisal terminated NICE TA351
| Formulary BNF 2.9
|
| Cannabis extract - Dekta-9- tetrahydrocannabinol (THC) 27mg and Cannabidiol (CBD) 25mg oromucosal spray | Sativex® | Refractory neuropathic pain. Not recommended for prescribing on the NHS in Lancashire and South Cumbria | Formulary BNF 2.7 |
| Capmatinib | Tabrecta | Advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal) - NICE TA884 Not recommended for prescribing on the NHS in Lancashire and South Cumbria | Formulary BNF |
| Capsaicin 179 mg (8%) Patches | Qutenza® | Peripheral neuropathic pain in non-diabetic patients | Formulary BNF 10.3
|
| Carfilzomib [with daratumumab and dexamethasone] | Kyprolis | Relapsed or refractory multiple myeloma in adults. Appraisal terminated - NICE TA841
Not recommended for prescribing on the NHS | Formulary BNF 8.1 |
| Carmustine implant | Gliadel® | Recurrent glioblastoma multiforme NICE TA149
Appraisal terminated. | Formulary BNF 8.1
|
| Casodex® | Casodex® | Generic Prescribing Only
| Formulary BNF 8.3
|
| Cemiplimab | Libtayo | Untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer in adults. Appraisal terminated NICE TA848 | Formulary BNF 8.1 |
| Cemiplimab | Libtayo | Recurrent or metastatic cervical cancer (terminated appraisal) NICE TA901 | Formulary BNF 8.1 |
| Cenegermin | Oxervate | Not recommended, within its marketing authorisation, for treating moderate to severe neurotrophic keratitis in adults - NICE TA532 | Formulary BNF 11 |
| Cetuximab | Erbitux® | Metastatic colorectal cancer 2nd line, (montherpay or combination chemo) NICE TA242 | Formulary BNF 8.1
|
| Cholestyramine 10% in cetomacrogol | | Refer patient back to original prescriber | Formulary BNF 13 |
Cilostazol
| Pletal® | Intermittent claudication NICE TA223 | Formulary BNF 2.6
|
| Ciltacabtagene | Carvykti | Relapsed or refractory multiple myeloma in adults - Appraisal Terminated - NICE TA889 | |
| Clarithromycin Straws | Clarosip® | Discontinued
| Formulary BNF 5.1
|
| Clarithromycin XL | Klaricid XL® | Respiratory tract infections
| Formulary BNF 5.1
|
| Co-aprovel® | Co-aprovel® | Generic Prescribing Only
| Formulary BNF 2.5
|
| Co-careldopa Intestinal Gel | Duodopa® | Severe Parkinson's disease | Formulary BNF 4.9
|
| Cobimetinib | Cotellic® | Unrescetable or metastatic BRAF V600 mutation positive melanoma, in combination with vemurafenib
NICE TA414 | Formulary BNF 8.1
|
Co-enzyme Q10/ Ubiquinone/ Ubidecarenone
| Co-enzyme Q10 | Except for mitochondrial disorders | Formulary BNF 9.8
|
| Colesevelam | Cholestagel® | Familial hypercholesterolaemia (combination or monotherapy) | Formulary BNF 2.12
|
| Co-phenotrope | all brands | Adjunct to rehydration in acute diarrhoea | Formulary BNF 1.4 |
| Co-proxamol | e.g. Cosalgesic®, Distalgesic®, Dolgesic®
| Unlicensed and only available on named patient basis | Formulary BNF 4.7
|
| Cozaar® | Cozaar® | Generic Prescribing Only
| Formulary BNF 2.5
|
| Crisaborole | | Mild to moderate atopic dermatitis - appraisal terminated. Not recommended for prescribing on the NHS in Lancashire. NICE TA701 | Formulary BNF 13.5.3 |
| Crizotinib | Xalkori® | Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene - not recommended by NICE TAG296 | Formulary BNF 8.1
|
| Dapoxetine | Priligy® | Premature ejaculation in men 18-64 years of age.
| Formulary BNF 7.4
|
| Daratumumab | Daralex ® | Relapsed or refractory multiple myeloma (with dexamethasone and lenalinomide), Appraisal terminated. | Formulary BNF 8.1.5 |
| Daratumumab | Daralex ®
| Daratuzumab with lenalidomide and dexamethasone for untreated multiple myeloma - appraisal terminated. NICE was unable to make a recommendation as the company did not provide an evidence submission. | Formulary BNF 8.1.5 |
| Daratumumab with pomalidomide and dexamethasone | Daralex® with Imnovid® and dexamethasone
| Relapsed or refractory multiple myeloma - Appraisal terminated - NICE TA726 Not recommended for prescribing on the NHS in Lancashire | Formulary BNF 8.1.5 |
| Darvadstrocel | Alofisel | Darvadstrocel is not recommended, within its marketing authorisation, for previously treated complex perianal fistulas in adults with non-active or mildly active luminal Crohn's disease. - NICE TA556 | Formulary BNF 1.5.2 |
| Dasatinib | Sprycel® | Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults - NICE TA714 - appraisal terminated. Not recommended for prescribing on the NHS in Lancashire | Formulary BNF 8.1.5 |
| Decitabine | Dacogen® | Leukaemia, acute myeloid NICE TA270. Appraisal terminated | Formulary BNF 8.1
|
| Degludec with Liraglutide | Xultophy® | Type II diabetes mellitus.
| Formulary BNF 6.1
|
Denosumab
| Xgeva® | Bone loss in non-metastatic prostate cancer NICE TA194 Terminated appraisal. | Formulary BNF 6.6
|
| Dexamethasone intravitreal implant | Ozurdex® | Repeat treatment for posterior uveitis.
Position Statement
| Formulary BNF 11.4
|
| Dexibuprofen | Seractil® | Pain & inflammation | Formulary BNF 10.1
|
| Dibotermin alfa | InductOs® | Non-union long bone fractures [unlicensed indication] | |
| Diclofenac Gel Patch | Voltarol Gel Patch® | Pain & inflammation | Formulary BNF 10.3
|
| Diclofenac tablets | All brands | Non Steroidal Anti Inflammatory Drug | Formulary BNF 4.7
|
| Dicycloverine | Non-proprietary | Intestinal smooth muscle relaxant | Formulary BNF 1.2
|
| Diethylamine salicylate cream | Algesal® | Rubifacient | Formulary BNF |
| Diovan® | Diovan® | Generic Prescribing Only | Formulary BNF 2.5
|
| Dosulepin | Prothiaden® | Depressive illness | Formulary BNF 4.3
|
| Diclofenac & Misoprostol | Arthrotec® | Rheumatoid arthritis; osteoarthritis | Formulary BNF 10.1
|
| Disofrol® | Disofrol® | Intractable cough, unlicensed import from USA | Formulary BNF 3.0
|
| Dupilumab | Dupixent® | Chronic rhinosinusitis with nasal polyps NICE TA648 | Formulary BNF 13 |
| Durvalumab | Durvalumab | Untreated extensive-stage small-cell lung cancer [terminated appraisal] NICE TA662 | Formulary BNF 8.1. |
| Duvelisib | | Relapsed follicular lymphoma after 2 or more systemic therapies - NICE TA717 - appraisal terminated. | Formulary BNF 8.1 |
| Duvelisib | Copiktra | NICE is unable to make a recommendation about the use in the NHS of duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments. NICE TA811 Appraisal terminated | Formulary BNF 8.1 |
| E-Cigarettes | E-Cigarettes | Substitute to smoking tobacco
Position statement
| Formulary BNF 4.10
|
| Eculizumab | Soliris® | Refractory myasthenia gravis - NICE TA636 - terminated appraisal | Formulary BNF 8.1.5 |
| Eculizumab | Soliris® | Relapsing neuromyelitis optica - NICE TA647 appraisal terminated | Formulary BNF 8.1. |
| Efalizumab | Raptiva® | Licence currently suspended. | Formulary BNF 10.1
|
| Elfornithine | Vaniqa® | Facial hirsutism | |
| Elotuzumab | Empliciti | Previously treated multiple myeloma (terminated appraisal) NICE TA434 | Formulary BNF 8.2.3 |
| Eltrompobag | Revolade® | Severe aplastic anaemia refractory to immunosuppressive therapy - terminated appraisal. NICE TA382
| Formulary BNF 9.1
|
| Enfortumab vedotin | Padcev | Previously treated locally advanced or metastatic urothelial cancer - NICE TA797. Not recommended for prescribign on the NHS in Lancashire | Formulary BNF |
Entocort®
| Entocort® | Prescribe as Budenofalk® | Formulary BNF 1.5
|
| Enzalutamide | Xtandi | Hormone-relapsed non-metastatic prostate cancer - not recommended by NICE TA580 | Formulary BNF |
| Erdosteine | Erdotin® | Acute exacerbations of chronic bronchitis | Formulary BNF 3.7
|
| Eribulin | Halaven® | Locally advanced or metastatic (secondary) breast cancer in adults who have had only 1 course of chemotherapy - not recommended as an option in NICE TA515 | Formulary BNF 8.1 |
| Erlotinib | Tarceva® | Monotherapy for maintenance treatment of non-small-cell lung cancer. NICE TA227 | Formulary BNF 8.1
|
| Escitalopram | Cipralex® | BLACK for Depression. GREEN for Generalised Anxiety Disorder | Formulary BNF 4.3
|
| Esketamine nasal spray | Spravato | Treatment-resistant depression in adults. Not recommended, within its marketing authorisation as by NICE TA854 | Formulary BNF 4.3 |
| Esketamine nasal spray | Spravato | Treatment of major depressive disorder in adults at imminent risk of suicide Appraisal terminated - see NICE TA899 | Formulary BNF 4.3
|
| Estriol 0.1% vaginal cream | Gynest® (Ortho) | Topical HRT | Formulary BNF 7.2 |
| Everolimus | Certican® | Preventing organ rejection in liver transplant. NICE TAG348
| Formulary BNF 8.1
|
| Everolimus | Certican® | Immunosuppressive therapy for kidney transplant in adults NICE TA481 (adults) NICE TA482 (Children and young adults) | Formulary BNF 8.2 |
| Evolocumab | Repatha® | Prevention of cardiac events on patients with CHD and a history of ACS , in combination with a statin | Formulary 2.12 |
| Ezetimibe & Simvastatin | Inegy® | Primary (heterozygous-familial & non-familial) cholesterolaemia Prescribe separately, NICE TA132 | Formulary BNF 2.12
|
| Fampridine | Fampyra® | Multiple sclerosis: mobility problems.
See NICE NG22 | NICE guidance NG 220
|
| Fentanyl Lozenge | Actiq® | Severe chronic pain | Formulary BNF 4.7
|
| Fentanyl nasal spray | Instanyl®, PecFent® | Severe chronic pain | Formulary BNF 4.7
|
| Fentanyl sublingual | Abstral®, Effentora® | Severe chronic pain | Formulary BNF 4.7
|
| Ferric Maltol | Feracrru® | Iron Deficiency Anaemia in patients with inflammatory bowel disease | Formulary BNF 9.1 |
| Fluconazole capsules & suspension | Diflucan® | Breast ductal thrush | Formulary BNF 5.2
|
| Fludarabine, oral | Fludara® | Leukaemia, lymphocytic, 1st line monotherapy NICE TA119 | Formulary BNF 8.1
|
| Fluocinolone Acetonide intravitreal implant | Iluvien® | Diabetic Macular Oedema NICE TA271 - replaced by NICE TA301 - RED Traffic Light | Formulary BNF 11.4
|
| Fluocinolone Acetonide intravitreal implant | Iluvien® | Chronic diabetic macular oedema that has inadequately responded to previous therapy, in adults whose eyes have natural lenses (phakic eyes). NICE TA613 | Formulary BNF 11.4
|
| Fluorouracil 0.5% + salicylic acid 10% | Actikerall® | Actinic keratosis | Formulary BNF 13.8
|
| Fluticasone & Formoterol inhaler | Flutiform® | Asthma | Formulary BNF 3.2
|
| Fluticasone furoate/Vilanterol | Relvar® Ellipta® | COPD in adults
Link to review
| Formulary BNF 3.1
|
| Fluticasone furoate | Avamys® | Nasal allergies | Formulary BNF 12.2
|
| Forceval® | Forceval® | BLACK for all indications except: Malabsorption = RED, | Formulary BNF 9.6
|
| Fulvestrant | Faslodex® | Breast cancer, locally advanced or metastatic. NICE TA239 | Formulary BNF 8.3
|
Fulvestrant
| Faslodex®
| Locally advanced or metastatic oestrogen-receptor positive breast cancer in post menopausal women who have not had endocrine therapy before | Formulary BNF 8.3 |
| Gabapentin Liquid | Non-proprietary | Seizures, neuropathic pain | Formulary BNF 4.8 |
| Gamolenic Acid | Efamast® Epogam® Evening Primrose Oil® | Dietary supplement | |
| Gefitinib | Iressa® | Lung cancer, NSC, 2nd line. NICE TA175
| Formulary BNF 8.1
|
| Gefitinib | Iressa® | Non-small-cell lung cancer that has progressed after prior chemotherapy. NICE TA374 | Formulary BNF 8.1
|
| Gemcitabine infusion | Non-proprietary | In combination with carboplatin for treating the first recurrence of platinum‑sensitive ovarian cancer, as perNICE TA389 | Formulary BNF 8.1
|
| Gentamicin & Hydrocortisone | Gentisone HC® | Eczematous inflammation in otitis externa | Formulary BNF 12.1 |
| Glasdegib with chemotherapy | | Untreated acute myeloid leukaemia NICE TA646 - appraisal terminated | Formulary BNF 8.1 |
| Glucosamine | Alateris®
Glusartel® | Osteoarthritis of the knee - NICE Do Not Do Recommendation | Formulary BNF 10.1
|
| Gluten Free Food Products | Gluten Free Food Products | Coeliac disease or other gluten intolerances. | Link to Commissioning Statement |
| Golimumab | Simponi® | BLACK for Methotrexate naive patients with Rheumatoid Arthritis. NICE TA224 RED as an option for Rheumatoid Arthritis NICE TA225, Psoriatic Arthritis NICE TA220 and Ankylosing Spondylitis NICE TA233 | Formulary BNF 10.1
|
| Golimumab | Simponi® | Moderate to severe active ulcerative colitis. Position Statement | Formulary BNF 1.5
|
| Grass pollen extract | Grazax®
| Grass & tree pollen allergy. New Drug Review
| Formulary BNF 3.4
|
| Haemophilus type b and Meningococcal group C conjugate vaccine | Menitorix | Adminstration in patients with rsepiratory conditions. Not recommended for prescribing on the NHS in Lancashire and South Cumbria. See supporting Document
| |
| Heliox® | Heliox® | Not commissioned for vocal chord dysfunction | |
| Hepatitis B Vaccine | | Travel vaccination | See Position Statement |
Hyaluronic Acid
| Durolane®, Euflexxa®, Fermathron®, Hyalgan®,
Orthovisc®, Ostenil®,
Ostenil Plus®, RenehaVis®
Suplasyn®, Synocrom®,
Synopsis®, Synvisc®, SportVis®
| Osteoarthritis (all joints) NICE CG177 (update of CG59) | Formulary BNF 10.1
|
| Hydrocortisone MR | Plenadren®
| Treatment of adrenal insufficiency
| Formulary BNF 6.3
|
| Hydrocortisone Sodium Phosphate eye drops | Softacort® | Treatment of mild non-infectious allergic or inflammatory conjunctival diseases. Not recommended for prescribing on the NHS in Lancashire and South Cumbria | Formulary BNF 9. |
Hydrogen peroxide 1% cream
| Crystacide®
| Skin infection, infected eczema
| Formulary BNF 13.11
|
Ibrutinib with bendamustine and rituximab
| | Relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal) NICE TA437 | Formulary BNF 8.1.5 |
| Ibrutinib | Imbruvica ▼
| Untreated chronic lymphocytic leukaemia without a 17p deletion or Tp53 mutation (terminated appraisal) | Formulary BNF 8.1.5 |
| Ibrutinib [with rituximab] | Imbruvica | Untreated chronic lymphocytic leukaemia (appraisal terminated) Not recommended for prescribing on the NHS in Lancashire NICE TA703 | Formulary BNF 8.1.5 |
Ibrutinib [with obinutuzumab]
| Imbruvica | Untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma in adults. (appraisal terminated) NICE TA702 | Formulary BNF 8.1.5 |
| Ibrutinib [with rituximab] | Imbruvica ▼ | (with rituximab) for treating Waldenstrom's macroglobulinaemia - NICE TA608 - appraisal terminated | Formulary BNF 8.1.5 |
Icatibant
| Firazyr®
| Hereditary angioedema in patients with C1-esterase inhibitor deficiency.
| Formulary BNF 3.4
|
Idelalisib
| Zydelic® ▼
| Follicular lymphoma that is refractory to 2 prior treatments (terminated appraisal)
NICE TA328
| Formulary BNF 8.1
|
| Idelalisib | Zydelic® ▼
| Chronic lymphocytic leukamia | Formulary BNF 8.1.5 |
| Idelalisib | Zydelic® ▼ | Not recommended,within its marketing authorisation, for traeting Follicular lymphoma that has not responded to 2 prior lines of treatment in adults. NICE TA604 | Formulary BNF 8.1 |
Idrolax®
| Idrolax®
| Osmotic laxative
| Formulary BNF 1.6
|
Imatanib, high dose
| Glivec®
| GIST, unresectable/ metastatic NICE TA209
| Formulary BNF 8.1
|
| Imipramine | Non-proprietary | Neuropathic Pain | Formulary BNF 4.7 |
Imiquimod 3.75%
| Zyclara®
| Actinic keratosis
| Formulary BNF 13.8
|
Influenza Vaccine (Intadermal)
| Intanza®
| 9 or 15 microgram / strain
| MMB Decision - INTERFACE
|
| Inositol Nicotinate | Hexopal® | Peripheral vascular disease. NICE TA223 | Formulary BNF 2.6 |
| Insulin glargine/lixisenatide | Suliqua®▼ | In combination with metformin for the treatment of adults with T2DM to improve glycaemic control when this has not been provided by metformin alone or metformin combined with another oral glucose lowering medicinal product or with basal insulin | Formulary BNF 6.1 |
| Intrabeam radiotherapy system | | Adjuvant treatment of early breast cancer NICE TA501 | |
| Isatuximab with carfilzomib and dexamethasone | Sarclisa® with Kyprolis® and dexamethasone
| Relapsed or refractory multiple myeloma - Terminated appraisal - NICE TA727 - Not recommended for prescribing on the NHS in Lancashire | Formulary BNF 8.1.5 |
| Japanese Encephalitis Vaccine | | Travel vaccination | See Position Statement |
| Ketamine (oral) | unlicensed | Chronic pain - limited clinical evidence. | Formulary BNF 4.7
|
| Ketamine infusion | | Non - fromulary | Formulary BNF 4.7 |
Lapatinib
| Tyverb®
| In combination with an aromatase inhibitor for women who have been through the menopause and who have metastatic breast cancer that is hormone receptor and HER2 positive. NICE TA257
| Formulary BNF 8.1
|
| Lenalidomide | Revlimid® | Untreated multiple myeloma - appraisal terminated - NICE TA603 | Formulary BNF 8.2.4 |
| Lenalidomide | Revlimid® | Relapsed or refractory mantle cell lymphoma - appraisal terminated - NICE TA774 Note recommended for prescribing on the NHS in Lancashire. | Formulary BNF 8.2.4 |
| Lesinurad | Ziurampic® | Chronic hyperuricaemia in adults with gout - not recommended by NICE TA506 | Formulary BNF |
Levocetirizine
| Xyzal®
| Antihistamine
| Formulary BNF 3.4
|
| Levomepromazine tablets 6mg | Non -proprietary | Pain, nausea, agitation in palliative care. | Formulary BNF 4.6 |
| Levothyroxine Liquid | | Hypothyroidism | Formulary BNF 6.2 |
| Lidocaine/Prilocaine Spray | Fortacin®
| Primary premature ejaculation in adult men | Formulary BNF 7.4.5 |
| Liothyronine 20mcg tablets | | Monotherapy for the chronic management of hypothyroidism - not licensed. Not for use by the NHS in Lancashire | |
| Liothyronine 20mcg tablets | | Management of resistant depression - not licensed, Not for use by the NHS in Lancashire | |
Liothyronine 20mcg tablets
| | Liothyronine therapy commenced in the private sector. Not recommended for prescribing on the NHS in Lancashire | |
| Lipitor® | Lipitor® | Generic prescribing only | Formulary BNF 2.12
|
| Liraglutide | Saxenda®
| Managing obesity in people aged 12 to 17 years - NICE TA749 (Appraisal terminated)
| Formulary BNF 6.1 |
| Loprazolam | Non-proprietary
| Hypnotic | Formulary BNF 4.1
|
Lormetazepam
| Non-proprietary
| Hypnotic | Formulary BNF 4.1
|
Losartan and Hydrochlorothiazide
| Cozaar Comp®
| Hypertension
| Formulary BNF 2.5
|
Losec®
| Losec®
| Generic Prescribing Only
| Formulary BNF 1.3
|
Loxapine
|
| Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder NICE TA286
| Formulary BNF 4.2
|
Lumacaftor-ivacaftor
| Orkambi
| Cystic Fibrosis in people 12 years and older who are homozygous for the F508del mutation
NICE TAG398
| Formulary BNF 3.7
|
Lumiracoxib
| Prexige®
| Discontinued | Formulary BNF 10.1
|
| Luspatercept | Reblozyl | Anaemia caused by beta-thalassaemia. Appraisal terminated NICE TA843 Not recommended for prescribing on the NHS | Formulary 8.1 |
| Luspatercept | Reblozyl | Anaemia caused by myelodysplastic syndromes. Appraisal terminated NICE TA844 Not recommended for prescribing on the NHS | Formulary 8.1 |
Lutein
| ICAPS®, Vitalux Plus® | Dietary supplement
| ICAPS - New Drug Review
|
Melatonin
| Circadin®
| Primary insomnia in adults
| Formulary BNF 4.1
|
| Melphalan | Phelinum | Haematological diseases before allogenic haematopoietic stem cell transplant - Appraisal terminated - NICE TA822 | Formulary BNF 8.1 |
| Meningitis Vaccine | | Travel Vaccination | See Position Statement |
| Mepolizumab | Nucala | Eosinophilic granulomatosis with polyangiitis in people 6 years and over. Appraisal terminated. NICE TA845 Not recommended for prescribing on the NHS | Formulary BNF 3.3 |
Mepolizumab
| Nucala | Severe hypereosinophilic syndrome in adults, Appraisal terminated. NICE TA846 Not recommended for prescribing on the NHS | Formulary BNF 3.3 |
Mepolizumab
| Nucala | Severe chronic rhinosinusitis with nasal polyps in adults. Appraisal terminated. NICE TA847 Not recommended for prescribing on the NHS | Formulary BNF 3.3 |
Methylnaltrexone
| Relistor® | Opioid-induced bowel dysfunction in people with advanced illness receiving palliative care NICE TAG277 & NICE TA468
| Formulary BNF 1.6
|
| Minocycline tablet | | Acne | Formulary BNF 13.6 |
Minocycline MR
| Acnamino®MR, Minocin MR®, Sebomin MR®
| Acne
| Formulary BNF 13.6
|
Mirapexin®
| Mirapexin®
| Generic Prescribing Only
| Formulary BNF 4.9
|
| Mitapivat | Pyrukynd® | Pyruvate kinase deficiency - appraisal terminated NICE TA867. Not to be prescribed on the NHS in Lancashire and South Cumbria | Formulary BNF |
Modulen IBD®
| Modulen IBD®
| Food supplement
| Formulary BNF
|
| Mosunetuzumab | Lunsumio | Relapsed or refractory follicular lymphoma in adults. NICE TA892. Not to be prescribed on the NHS in Lancashire and South Cumbria | Formulary 8.2.3 |
Mugard®
| Mugard®
| Mucositis from cancer therapy
| Formulary BNF 12.3
|
| Mycophenolate Sodium | Myfortic®, Ceptava®
| Immunosuppressive therapy for kidney transplant in adults NICE TA481 (adults) NICE TA482 (Children and young adults) | Formulary BNF 8.2 |
| Naproxen & Esomeprazole | Vimovo®
| Pain & inflammation
| Formulary BNF 10.1
|
| Naltrexone-bupropion | Mysimba® | Management of overweight and obesity in adults NICE TA494 Not recommended for prescribing on the NHS | Formulary BNF 4. |
Naltrexone
| Nalorex® Opizone® | Treatment of advanced ovarian cancer
| Formulary BNF 4.
|
Nebulised Amoxycillin
|
| Not licensed for use via nebulised route for bronchiectasis or any other indication
| Formulary
|
Necitumumab
| Portrazza
| Untreated advanced or metastatic squamous non-small-cell lung cancer. NICE TA411
| Formulary BNF 8.2
|
| Nefopan | all brands | Non opioid analgesia | Formulary BNF 4.7 |
Nicotine Strips
| NiQuitin Strips®
| Nicotine Replacement Therapy
| Formulary BNF 4.10
|
| Nivolumab | Opdivo® | Not recommended within its marketing authorisation , for treating locally advanced unresectable or metastatic urothelial carcinoma in adults - as per NICE TA530 | Formulary BNF 8.1.5 |
| Nivolumab with ipilimumab and chemotherapy | Opdivo® with Yervoy and chemotherapy | Not recommended within its marketing authorisation for untreated metastatic non-small-cell lung cancer - NICE TA724 | Formulary BNF 8.1.5 |
Norfloxacin
| Utinor®
| Prophylaxis of spontaneous bacterial peritonitis
| Formualry BNF 5.1
|
| Nortriptyline | Non-proprietary | Depressive illness | FormularyBNF 4.3 |
Ofatumumab
| Arzerra®
| Chronic lymphocytic leukaemia, NICE TA202 | Formulary BNF 8.2
|
| Ofatumumab | Arzerra® | Chronic lymphocytic leukaemia (with chemotherapy) | Formulary BNF8.2.3 |
| Olanzapine Embonate Depot Injection | ZypAdhera®
| Schizophrenia
| Formulary BNF 4.2
|
| Olaparib | Lynparza® | BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy. NICE TA762 [terminated appraisal] | Formulary BNF 8.1 |
| Olaparib | Lynparza® | Maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy. NICE TA750 (Appraisal terminated) | Formulary BNF 8.1.5 |
| Olopatadine hydrochloride and Mometasone Furoate Monohydrate nasal spray | Ryaltris® | Treatment of moderate to severe nasal symptoms associated with allergic rhinitis in adults and adolescents aged 12 years and older | Formulary BNF 12.2 |
Omalizumab
| Xolair®
| BLACK for children under 6 . RED for adults and children over 6. NICE TA278 | Formulary BNF 3.3
|
| Omalizumab | Xolair® | Chronic rhinosinusitis with nasal polyps.
Not recommended for prescribing on the NHS in Lancashire. NICE TA678 (Appraisal terminated)
|
Formulary BNF 3.4. |
Omega-3 acid ethyl esters
| Omacor® | Hyper-triglyceridaemia. NHS England has identified this product as an item that should not be routinely prescribed in primary care. It is available to purchase over the counter | Formulary BNF 2.12 |
| Omeprazole liquid | Non-proprietary | Gastro-oesophageal reflux | Formulary BNF 1.3.5 |
| Ospemifene | Senshio® | Moderate to severe symptomatic vulvar and vaginal atrophy in post-menopausal women who are not candidates for local vaginal oestrogen therapy | Formulary BNF 7.2.1 |
Oxycodone hydrochloride/ naloxone hydrochloride
| Targinact®
| Restless Legs Syndrome
| Formulary BNF 4.9
RLS Guidelines
|
Oxycodone hydrochloride/ naloxone hydrochloride
| Targinact®
| Severe pain
| Formulary BNF 4.7
|
| Ozanimod | Zeposia® | Relapsing–remitting multiple sclerosis in adults with clinical or imaging features of active disease. Not recommended for prescribing on the NHS in Lancashire - NICE TA706 | Formulary BNF 8.2 |
Omega-3 acid ethyl esters
| Omacor®
| Post Myocardial Infarction. NHS England has identified this product as an item that should not be routinely prescribed in primary care. It is available to purchase over the counter
| Formulary BNF 2.12
|
Paclitaxel
| Abraxane®, Taxol® | Breast cancer, early (NICE TA108)
| Formulary BNF 8.1
|
Paclitaxel
| Abraxane®
| Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal). NICE TA362
| Formulary BNF 8.1
|
| Padeliporfin | Tookad® | Padeliporfin is not recommended, within its marketing authorisation, for untreated, unilateral, low-risk prostate cancer in adults - NICE TA546 | Formulary BNF |
Paliperidone tablets
| Invega®
| Schizophrenia
| Formulary BNF 4.2
|
Panitumumab (in combination with chemotherpay)
| Vectibix®
| Metastatic colon cancer (appraisal terminated) NICE TA240 updated March 17
| Formulary BNF 8.1
|
Panitumumab
| Vectibix®
| Monotherpay of metastatic colorectal cancer 2nd line (NICE TA242)
| Formulary BNF 8.1.5
|
Paricalcitol
| Zemplar®
| Secondary hypoparathyroidism
| Formulary BNF 9.6
|
Pegaptanib
| Macugen®
| Age-related macular degeneration, (NICE TA155) | Formulary BNF 11.8
|
Pegloticase
| Krystexxa®
| Gout (NICE TA291)
| Formulary BNF 10.
|
| Pegylated liposomal irinotecan | Onivyde | Pancreatic cancer in adults after gencitabine (NICE TA440) | Formulary BNF 8.1 |
| Pembrolizumab | Keytruda® | Not recommended as an option to treat relapsed or erfarctory classical Hodgkin lymphoma in adults who have had auologous atem cell transplant and brentuximab vedotin as per NICE TA540 | Formulary BNF 8.1 |
| Pembrolizumab | Keytruda® | Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (NICE TA570) - appraisal terminated.
NOT recommended for prescribing on the NHS in Lancashire
| Formulary BNF 8.1.5 |
| Pembrolizumab | Keytruda® | Not recommended, with axitinib, for untreated advanced renal cell carcinoma NICE TA650 | Formulary BNF 8.1.5 |
| Pembrolizumab | Keytruda® | Not recommended for prescribing on the NHS in Lancashire NICE TA674 [appraisal terminated] | Formulary BNF 8.1 |
| Pembrolizumab | Keytruda® | Locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy in adults - NICE TA692 [replaces NICE TA519] Not recommended for prescribing on the NHS in Lancashire | Formulary BNF 8.1 |
Pentoxifylline
| Trental®
| Peripheral vascular disease, (NICE TA223) | Formulary BNF 2.6
|
Perindopril Arginine
| Coversyl®
| Use generic perindopril erbumine
| Formulary BNF 2.5
|
Pioglitazone15mg/ Metformin 850mg
| Competact®
| Type 2 diabetes mellitus
| Formulary BNF 6.1
|
| Pitolisant | Wakix® | Narcolepsy with or without cataplexy in adults | Formulary BNF 4.4 |
| Pitolisant hydrochloride | | Not recommended, within its marketing authorisation: Excessive daytime sleepiness caused by obstructive sleep apnoea - NICE TA776 , Not recommended for prescribing on the NHS in Lancashire | Formulary BNF 4 |
Plavix®
| Plavix® | Generic prescribing only - Plavix may be supplied against a generically written prescription.
| Formulary BNF 2.9
|
| Pomalidomide | Imnovid® | Relapsed or refractory multiple myeloma (with bortezomib and dexamethasone) - NICE TA602 - appraisal terminated | Formulary BNF 8.2.4 |
| Potassium hydroxide 5% | Molludab ® | Molluscum | Formulary BNF |
| Prasterone | Intrarosa® | Vulvar and vaginal atrophy in postmenopausal women having moderate to severe symptoms | Formulary BNF 7.2 |
| Pralsetinib | Gavreto | Pralsetinib is not recommended, within its marketing authorisation, for treating RET fusion-positive advanced non-small-cell lung cancer (NSCLC) in adults who have not had a RET inhibitor before. NICE TA812 | Formulary BNF 8.1 |
Praxilene®
| Praxilene®
| Generic prescribing only
| Formulary BNF 2.6
|
| Prednisolone Soluble | All brands
| Suppression of inflammation and allergic disorders
| Formulary BNF 6.3
|
Prednisolone 5mg EC
| Deltacortril®
| Use non-EC tabs, where possible, 2.5mg EC tabs remain GREEN
| Formulary BNF 6.3
|
Prednisone
| Lodatra®
| Moderate to severe rheumatoid arthritis
| Formulary BNF 6.3
|
Pregabalin
| Lyrica®
| Generalised Anxiety disorder Joint Formulary for Psychotropic Medication LCFT
| Formulary BNF 4.3
|
Pregabalin
| Lyrica®
| Epilepsy only
| Formulary BNF 4.8
|
| Pregabalin Liquid | all brands | Epilepsy, GAD, neuropathic pain | Formulary BNF 4.7 |
Progesterone Cream
|
| Unlicensed
| Formulary BNF 6.4
|
| Promethazine tablets 10mg, 25mg, liquid 5mg/5mL | Promethazine | Not to be prescribed as a hypnotic: non-formulary indication consistent with the advice in the BNF that has determined that promethazine is “less suitable for prescribing" | Formulary BNF 4.1 |
| Rabies vaccine | | Travel vaccination | See Position Statement |
Ramucirumab
| Cyramza®
| Advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy.
NICE TAG 378
| Formulary BNF 8.3 |
Ramucirumab
| Cyramza®
| locally advanced or metastatic non-small-cell lung cancer , in combination with docetaxel, in adults whose disease has progressed after platinum-based chemotherapy. NICE TA403
| Formulary BNF 8.1
|
Ramucirumab
| Cyramza®
| With erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer NICE TA635 - terminated appraisal | Formulary BNF 8.1.5 |
| Ramucirumab | Cyramza® | Unresectable hepatocellular carcinoma in adults who have had sorafenib - NICE TA609 - terminated appraisal | Formulary BNF 8.1 |
| Ranibizumab | Lucentis® | Diabetic retinopathy - NICE TA637 - terminated appraisal | Formulary BNF 11.8.2 |
| Recombinant human parathyroid hormone | | Hypoparathyroidism - appraisal terminated | Formulary 6.6 |
Regorafenib
| Stivarga®
| Metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) NICE TA334
| Formulary BNF 8.1
|
| Regorafenib | Stivarga® | Previously treated advanced hepatocellular carcinoma in adults - not recommended as an option in NICE TA514 | Formulary BNF 8.1 |
RESPeRATE ®
| RESPeRATE®
| Black for Adjunct treatment of Hypertension
| Formulary BNF 2.5
|
Retapamulin
| Altargo®
| Superficial bacterial infections
| Formulary BNF 13.10
|
| Ripretininb | Qinlock | Not recommended for treating advanced gastrointestinal stromal tumour in adults after 3 or more treatments as by NICE TA881 | Formulary BNF 8.1 |
Risedronate
| Actonel®
| Osteoporosis, primary prevention (NICE TA160)
| Formulary BNF 6.6
|
Rituximab
| MabThera®
| Pemphigus
| Formulary BNF 8,2
|
Rituximab
| MabThera®
| Multi drug resistant, steroid dependent, frequently relapsing nephrotic syndrome
| Formulary BNF 8.2
|
Rituximab
| MabThera®
| Resistant coeliac disease
| Formulary BNF 8.2
|
| Ruxolitinib | | Acute graft versus host disease refractory to corticosteroids in people aged 12 and over. Appraisal terminated NICE TA839 | Formulary BNF 8.1 |
| Ruxolitinib | | Chronic graft versus host disease refractory to corticosteroids in people aged 12 and over. Appraisal terminated. NICE TA840 | Formulary BNF 8.1 |
| Safinamide | Xadago®
| Idiopathic Parkinson's disease
New Medicines Recommendation | Formulary BNF 4.9
|
Salbutamol SR tablets
| Ventmax SR®
| Asthma
| Formulary BNF 3.1
|
Salmeterol MDI
| Neovent®
| Asthma
| Formulary BNF 3.1
|
Sea Water nasal drops
| Sterimar®
| Nasal decongestant
| Formulary BNF 12.2
|
Selenium
| Oral food supplement
| Post bariatric surgery - patient to purchase own. link to Guidelines
| Formulary BNF 9.5
|
| Selinexor [with low dose dexamethasone] | | Refractory multiple myeloma in adults. Appraisal terminated. Not recommended for prescribing on the NHS in Lancashire NICE TA700 | Formulary BNF 8.1.5 |
Sertindole
| Serdolect®
| Schizophrenia
| Formulary BNF 4.2
|
Silicone Gel Sheets
| Scarsil®, Silgel STC-SE®, Dermatix®, Ciltech®, NewGel®, Kelocote®, Advasil Conform ®, Cica-Care®
| Hypertrophic and keloid scarring
| Formulary woundcare
|
Silk Garments
| Dermasilk®, Dreamskin®, Skinnies Silk TM | Eczema/atopic dermatitis
| ELHE Position statement
|
Simeprevir
| Olysio®
| Simeprevir in combination with sofosbuvir for treating genotype 1 or 4 chronic hepatitis C (terminated appraisal). NICE TA361
| Formulary BNF 5.3
|
Simvastatin Suspension
| Rosemont brand
| Primary hypercholesterlaemia
| Formulary BNF 2.12
|
Sipuleucel-T
|
| Asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer as by NICE TA332
| Formulary BNF 8.3
|
| Sirolimus | Rapamune® | Immunosuppressive therapy for kidney transplant in adults NICE TA481 (adults) NICE TA482 (Children and young adults) | Formulary BNF 8.2 |
Sitagliptin & Metformin
| Janumet®
| Type II Diabetes, (prescribe drugs separately) | Formulary BNF 6.1
|
| Slow-release potassium bicarbonate-potassium citrate | Sibnayal | Distal renal tubular acidosis- Appraisal terminated- not recommended for prescribing on the NHS in Lancashire | Formulary BNF 9.2 |
Sodium Chondroitin sulphate 2% bladder washout
| Uracyst®
| Painful bladder syndrome
| Formulary BNF 7.4
|
Sodium Hyaluronate Injection
| Durolane® Hyalgan® Ostenil®
| BLACK for OA of the knee. RED for all other indications | Formulary BNF 10.1
|
Solifenacin 6mg/ tamsulosin 400mcg MR
| Vesomni®
| Symptoms associated with benign prostatic hyperplasia
| Formulary BNF 7.4
|
| Solriamfetol | | Not recommended, within its marketing authorisation. to improve wakefulness and reduce excessive daytime sleepiness in adults with obstructive sleep apnoea - see NICE TA777 | |
Sorafenib
| Nexavar®
| Renal cell carcinoma (NICE TA178)
| Formulary BNF 8.1
|
| SQ HDM SLIT | Acarizax | Treating allergic rhinitis and allergic asthma in adults caused by house dust mites. Not Recommended for prescribing on the NHS in Lancashire. APPRAISAL TERMINATED NICE TA834
| Formulary BNF 3.4 |
| St Johns Wort (Hypericum) | | Depression
| Formulary BNF 4.3
|
Sunitinib
| Sutent®
| Renal cell carcinoma (NICE TA178)
| Formulary BNF 8.1
|
| Tacrolimus Prolonged Release | Advagraf®, Envarsus | Immunosuppressive therapy for kidney transplant in adults NICE TA481 (adults) NICE TA482 (Children and young adults) | FormularyBNF 8.2 |
Tadalafil
| Cialis®
| Benign prostatic hyperplasia
(NICE TA273)
| Formulary BNF 7.4
|
Tadalafil once daily
| Cialis®
| Post prostatectomy
| Formulary BNF 7.4
|
Tadalafil 2.5, 5mg
| Cialis®
| Erectile Dysfunction
| Formulary BNF 7.4
|
| Tafamidis | Vyndaqel®
| Transthyretin amyloidosis with cardiomyopathy. Not recommended for prescribing on the NHS in Lancashire.
NICE TA696 | Formulary BNF 4.9 |
| Tafasitamab with lenalidomide | Minjuvi | Relapsed or refractory diffuse large B-cell lymphoma in adults who cannot have an autologous stem cell transplant - NICE TA883
Not recommended for prescribing on the NHS in Lancashire and South Cumbria | Formulary BNF 8.1 |
| Tagrazofusp | Elzonris | Blastic plasmacytoid dendritic cell neoplasm (terminated appraisal) - NICE TA782 - Not recommended for prescribing on the NHS in lancashire | Formulary BNF |
Tamsulosin MR Tablets
| Flomaxtra XL®
| Benign prostatic hyperplasia
| Formulary BNF 7.4
|
Tapentadol MR
| Palexia SR®
| Not recommended for use as a treatment option for intractable neuropathic pain in non-palliative care patients. Link to Position Statement
| Formulary BNF 4.7.2
|
Tapentadol MR
| Palexia SR®
| Not recommended for use as a treatment for non-specific pain. Link to Position Statement
| Formulary BNF 4.7
|
Taurine
| Taurine
| Supplementation in Cystic Fibrosis Liver Disease
|
|
| Teclistamab | Tecvayli® | Realpsed or refractory multiple myeloma after 3 or more therapies = appraisal terminated NICE TA869 Not to be prescribed on the NHS in Lancashire and South Cumbria | Formulary BNF 8.1 |
Telbivudine
| Sebivo®
| Chronic Hepatits B
| Formulary BNF 5.3
|
Temsirolimus
| Torisel®
| Renal cell carcinoma (NICE TA178)
| Formulary BNF 8.1
|
Temsirolimus
| Torisel®
| Mantle Cell Lymphoma, (NICE TA207) | Formulary BNF 8.1
|
| Tenofovir alafenamide | | Chronic hepatitis B (terminated appraisal) NICE TA 435 | Formulary BNF 8.2.3 |
Testosterone gel
| Testim®
| Female sexual dysfunction post oophorectomy or primary ovarian failure
| LMMG new medicine assessment
|
| Testosterone patches Testosterone mucoadhesive buccal tablets. Testosterone gel | Intrinsa®
Striant SR®
Testogel®
| Hypoactive sexual desire in surgically induced menopause. Link to New Drug Review
| Formulary BNF 6.4
|
| Testosterone mucoadhesive buccal tablets | Striant SR®
| Hypogonadism
| Formulary BNF 6.4
|
| Testosterone Patches Testosterone mucoadhesive buccal tablets Testosterone gel | Intrinsa®
Striant SR®
Testogel®
| Male low libido
| Formulary 6.4 |
| Tick Borne Encephalitis vaccine | | Travel vaccination | See Position Statement |
| Tisagenlecleucel | Kymriah® | Relapsed or refractory follicular lymphoma in adults after 2 or more therapies. Appraisal terminated. NICE TA842 Not recommended for prescribing on the NHS in Lancashire. | Formulary 8.2.4 |
| Tixagevimag | Evusheld® | Tixagevimab plus cilgavimab is not recommended, within its marketing authorisation, for preventing COVID-19 - See NICE TA900 | Formulary 5.3 |
Tolvaptan
| Samsca®
| Hyponatraemia
| Formulary BNF 6.5
|
Topotecan, IV
| Non-proprietary
| Lung cancer, small cell (NICE TA184)
| Formulary BNF 8.1
|
Topotecan, IV
| Non-proprietary
| Not recommended within its marketing authorisation for treating the first recurrence of platinum‑sensitive ovarian cancer. NICE TA389
| Formulary BNF 8.1
|
Topotecan, IV
| Non-proprietary
| Recurrent platinum‑resistant or platinum‑refractory ovarian cancer (not recommended) in NICE TA389
| Formulary BNF 8.1
|
Trabectedin
| Yondelis®
| Relapsed platinum sensitive ovarian cancer when in combination with PLDH. (NICE TA222) | Formulary BNF 8.1
|
Trabectedin
| Yondelis®
| Trabectedin in combination with PLDH is not recommended within its marketing authorisation for treating the first recurrence of platinum‑sensitive ovarian cancer. NICE TA389
| Formulary BNF 8.1
|
Tramadol and Paracetamol
| Tramacet®
| Moderate to severe pain
| Formulary BNF 4.7
|
Trastuzumab
| Herceptin®
| In combination with an aromatase inhibitor for women who have been through the menopause and who have metastatic breast cancer that is hormone receptor and HER2 positive (NICE TA257)
| Formulary BNF 8.1
|
| Trastuzumab deruxtecan | Enhertu | HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment. Appraisal terminated NICE TA879 | Formulary BNF 8.1 |
Triamcinolone Hexadetonide Injection
|
| Approved for use for JIA only in ELHE - Not approved for other indications
| Formulary BNF 10.1
|
| Trimipramine | | Depressive illness/neuropathic pain | Formulary BNF 4.3 |
| TYRX Absorbable Antibacterial Envelope | | Preventing infection from cardiac implantable electronic devices - appraisal terminated - nor recommended for prescribing on the NHS in Lancashire | Formulary BNF |
| Ulipristal | Esmya® | Intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. See MHRA Alert February 2018 | Formulary 6.4 |
Umeclidinium
| Incruse®▼
| COPD | Formulary BNF 3.1
|
Valsartan and Amlodipine
| Exforge®
| Hypertension
| Formulary BNF 2.6
|
| Vandetanib | Caprelsa | Vandetanib is not recommended, within its marketing authroisation , for treating aggressive and symtomatic medullary thyroid canmer in adults as in NICE TA550 | Formulary BNF 8. |
Vardenafil
| Levitra®
| Those patients prescribed this before July 2012 may continue on it
| Formulary BNF 7.4
|
| Vedolizumab | Entyvio | Chronic refractory pouchitis after surgery for ulcerative colitis in adults - Appraisal terminated NICE TA826 | Formulary BNF |
| Vericiguat | Verquvo® | Chronic heart failure with reduced ejection fraction in adults. Terminated appraisal - NICE TA731. Not recommended for prescribing on the NHS in Lancashire | Formulary BNF 4. |
| Vernakalant | Brinavess | Rapid conversion of recent onset atrial fibrilation to sinus rhythm in adults . Not recommend for prescribing on the NHS in Lancashire. NICE TA675 [appraisal terminated] |
Formulary BNF 2.3.2 |
Viagra®
| Viagra®
| Generic Prescribing Only
| Formulary BNF 7.4
|
Vinflunine
| Javlor®
| Urothelial tract carcinoma
| Formulary BNF 8.1
|
Vildagliptin
| Galvus®
| Type II Diabetes / Use sitagliptin | Formulary BNF 6.1
|
| Vismodegib | Erivedge | Basal cell carcinoma | Formulary BNF 8.1 |
Vitamin D capsules
| Fultium®
| Vitamin D deficiency
| Formulary BNF 9.6
|
| Vitamins, minerals, supplements, herbal and homeopathic medicines without a product licence | | Link to position statement | Formulary BNF 9 |
| Yellow fever Vaccine | | Travel vaccination | See Position Statement |
Zinc
| Oral food supplement
| Post bariatric surgery - patient to purchase own
| |
| | | | |
| | | | |
| | | | |
